http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2006189680-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_604de923c4a6564a4c1003b293f71d8d http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6c937aa8f3ede5894daac874518a2096 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-353 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-353 |
| filingDate | 2006-01-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8014700d9f46ab0e82591084153bf783 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_feb498eb463a77e2ead44b350ec85aae |
| publicationDate | 2006-08-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2006189680-A1 |
| titleOfInvention | Apigenin for chemoprevention, and chemotherapy combined with therapeutic reagents |
| abstract | Apigenin is a nontoxic compound. The present invention is appropriate for apigenin use in people who have a high risk of getting cancer, and in people who have cancer through chemoprevention and chemotherapy, respectively. We showed that apigenin inhibited cancer cell proliferation, tumor growth and angiogenesis. Apigenin selectively inhibited proliferation and induced apoptosis of cancer cells, enhanced the sensitivity of different cancer cells to different therapeutic drugs including cisplatin and taxol. Apigenin also inhibits angiogenesis and tumor growth in human cancers, and inhibits angiogenic inducers such as hypoxia-inducible factor 1 (HIF-1) and vascular endothelial growth factor (VEGF). Apigenin inhibited expression of HIF-1 and VEGF through PI3K, AKT, p70S6K1 and HDM2 pathways, which are commonly observed in all kinds of human cancers. Thus, our results indicate that apigenin can be applied to various human cancers for chemoprevention, and for chemotherapy when combined with other therapeutic reagents. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018043989-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2009006555-A2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2403497-A4 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2403497-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010062078-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011142815-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2178531-A4 |
| priorityDate | 2005-01-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 43.